Q3
CMND — Q3 2026 Financial Report Analysis
Clearmind ended its fiscal Q3 (to July 31, 2026) with $12.0M cash after a 135-fold rise in share count, then spent $4.0M on an EV-charging start-up; its alcohol-use-disorder drug CMND-100 has just dosed its first patients.